硫普罗宁对晚期非小细胞肺癌化疗影响的研究

目的:研究抗氧化剂硫普罗宁对晚期非小细胞肺癌化疗的影响?方法:筛选江苏省肿瘤医院化疗科2004年6月~2007年12月的患者病例资料?在一线化疗过程中合并使用硫普罗宁的晚期非小细胞肺癌病例为硫普罗宁联合化疗组(A组),并随机选择同等数目的未合并使用硫普罗宁的晚期非小细胞肺癌一线化疗患者为对照组(B组)?运用Stata 8.0统计软件分析比较两组间化疗的疗效?不良反应及生存情况?结果:总计246例病例纳入研究?A组和B组化疗有效率分别为22.0%和19.5%,临床获益率分别为78.9%和74.0%,差异均无统计学意义(P > 0.05);白细胞降低发生率分别为41.5%和54.4%(P=0.041),差异有统计学意义;A组和B组的中位生存时间分别为11.895%可信区间(confidence interval,CI):10.2~13.8]个月和9.8(95%CI:8.7~11.3)个月,中位疾病无进展时间分别为6.2(95%CI:4.4~8.2)个月和4.5(95%CI:4.2~6.4)个月,差异均无统计学意义(P > 0.05);一年生存率分别为48.8%和35.8%(P=0.028),差异有统计学意义?结论:在晚期非小细胞肺癌一线化疗中合并使用抗氧化剂硫普罗宁虽未明显提高化疗近期疗效及延长生存时间,但可减轻化疗所致白细胞降低并提高一年生存率?

Impact of tiopronin on chemotherapy for advanced or metastatic non-small-cell lung cancer

Objective:To evaluate the effect of the antioxidant tiopronin on chemotherapy in patients with advanced or metastatic non-small-cell lung cancer(NSCLC). Methods:Study subjects included the patients with advanced or metastatic NSCLC diagnosed and treated between June 2004 and December 2007 at Jiangsu Cancer Hospital & Research Institute. The patients(Group A)were treated with tiopronin combined with first-line chemotherapy. We ramdomly selected the same number of advanced or metastatic NSCLC patients who were not treated with tiopronin during first-line chemotherapy as control group(Group B). A total of 246 patients were enrolled. All data were analyzed using the State 8.0 statistical software. Results:The objective response rate of Group A versus Group B were 22.0% versus 19.5%(P=0.64),and disease control rate were 78.9% versus 74.0%(P=0.37),respectively. In Group B patients had higher neutropenia(54.4%)than that in Group A(41.5%)(P=0.041). The median progression-free survival of two groups were 6.295% confidence interval(CI),4.4~8.2]and 4.5(95%CI:4.2~6.4)months,respectively,with corresponding median overall survival were 11.8(95%CI:10.2~13.8)and 9.8(95%CI:8.7~11.3)months(P > 0.05). 1-year overall survival rates for patients in Group A and Group B were 48.8% and 35.8%(P=0.028),respectively. Conclusion:There were no differences in overall survival,progression-free survival,response rates and disease control rate between two groups,but tiopronin concurrent with first-line chemotherapy could reduce neutropenia and improve 1-year overall survival in patients with advanced or metastatic NSCLC.